Kamada starts Alpha-1 Antitrypsin phase 2 clinical trial to prevent lung transplant rejection
Kamada has started a phase 2 clinical trial with its proprietary drug Alpha-1 Antitrypsin (AAT) for preventing rejection in lung transplants, as part of a collaboration with Baxalta.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Alpha-1 Antitrypsin Deficiency | Clinical Trials | Lung Transplant | Pharmaceuticals | Transplant Surgery | Transplants